SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.

about

Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.

P2860

Q47137275-921E1CE4-868C-4FFE-B55A-F67419E47EC2

P2860

SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q38757910

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.

@en

type

Item

label

SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.

@en

prefLabel

SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.

@en

P1476

SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.

@en

P2093

Chansu Lee

http://www.w3.org/2001/XMLSchema#string

Hyoung Doo Shin

http://www.w3.org/2001/XMLSchema#string

Hyun Sub Cheong

http://www.w3.org/2001/XMLSchema#string

Hyung-Lae Kim

http://www.w3.org/2001/XMLSchema#string

Jeong-Hyun Kim

http://www.w3.org/2001/XMLSchema#string

Kwang-Sung Ahn

http://www.w3.org/2001/XMLSchema#string

Sung-Soo Yoon

http://www.w3.org/2001/XMLSchema#string

Youngil Koh

http://www.w3.org/2001/XMLSchema#string

P2860

Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis

Score tests for association between traits and haplotypes when linkage phase is ambiguous

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.

Potential mechanisms of resistance to cytarabine in AML patients.

A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants.

Drug resistance in childhood acute myeloid leukemia.

Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.

Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity.

Genetic factors influencing cytarabine therapy.

P2888

s00280-016-3103-x

P304

533-540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-016-3103-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1021706117

http://www.w3.org/2001/XMLSchema#string

P698

27422302

http://www.w3.org/2001/XMLSchema#string

SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.

about

P2860

P2860

SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698